AZGP1 and obesity disorder: Consistent with the observed resistance to obesity, a fasting-refeeding experiment showed that HFD-fed mice injected with AAV-Azgp1 into the MBH had lower fasting and postprandial blood glucose levels (Supplementary Fig. 2a).